Tokyo, Apr 22, 2011 (JCN Newswire) - Eisai Co., Ltd. (TSE: 4523) announced today that it has received approval to market its novel anticancer Halaven(R) Injection 1mg (eribulin mesylate) in Japan for the treatment of inoperable and recurrent breast cancer. Discovered and developed by Eisai, Halaven is now approved in each of the world’s three largest pharmaceutical markets, comprising Japan, the United States and the European Union (EU).
